Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.

Colevas, A. Dimitrios; Busse, Paul M.; Norris, Charles M.; Fried, Michael; Tishler, Roy B.; Poulin, Muriel A.; Fabian, Richard L.; FitzGerald, T.J.; Dreyfuss, Arnon I.; Peters, Edward S.; Adak, Sudeshna; Costello, Rosemary; Barton, J. J.; Posner, Marshall R.

doi:10.1200/jco.1998.16.4.1331

Cited by 93 publications

(43 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three trials conducted at the Dana-Farber Cancer Institute administered docetaxel with PFL in SCCHN patients with advanced disease, who were potentially curable (Table 2) (Colevas et al, 1998;. In the first study, TPFL-5, 23 patients with stage III -IV SCCHN received docetaxel 25 -60 mg m À2 d1 (day 1), cisplatin 25 mg m À2 d1 -5, 5-FU 700 mg m À2 (N ¼ 21) or 800 mg m À2 (N ¼ 2) d2 -5 and leucovorin 500 mg m À2 d1 -5 every 4 weeks for three cycles (Colevas et al, 1998).…”

Section: Docetaxel Plus Modified Pfl Regimensmentioning

confidence: 99%

“…In the first study, TPFL-5, 23 patients with stage III -IV SCCHN received docetaxel 25 -60 mg m À2 d1 (day 1), cisplatin 25 mg m À2 d1 -5, 5-FU 700 mg m À2 (N ¼ 21) or 800 mg m À2 (N ¼ 2) d2 -5 and leucovorin 500 mg m À2 d1 -5 every 4 weeks for three cycles (Colevas et al, 1998). The ORR prior to definitive, twice daily radiation therapy was 100%, consisting of 14 Dreyfuss et al (1996) 100 mg m À2 29 42 d1 q3w Couteau et al (1999) 100 mg m À2 21 21 d1 q3w complete responses (CRs; 61%) and nine partial responses (PRs; 39%).…”

Section: Docetaxel Plus Modified Pfl Regimensmentioning

confidence: 99%

“…Updated survival data (median follow-up 43 months) revealed both the 3-year overall survival and disease-free survival rates to be 78% . Approximately 40% of patients receiving the maximum tolerated dose (MTD) of docetaxel were hospitalised for neutropenia despite administration of granulocyte colony-stimulating factor (G-CSF) d5 -10 and ciprofloxacin d5 -15 (Colevas et al, 1998). Mucositis was the most prominent grade III -IV nonhaematological toxicity (46% of cycles), followed by nausea (11% of cycles) and diarrhoea (11% of cycles).…”

Section: Docetaxel Plus Modified Pfl Regimensmentioning

confidence: 99%

See 2 more Smart Citations

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction chemotherapy or chemoradiotherapy, but to date without major impact on survival. The combination of cisplatin -5-fluorouracil (5-FU) (PF) has been used as standard induction therapy; however, poor patient survival has stimulated investigation into new agents with potential activity in SCCHN. Docetaxel has significant single-agent activity in SCCHN and has been investigated in combination with PF regimens as induction therapy. The results of six phase II studies of docetaxel -PF regimens (TPF) as induction in locally advanced SCCHN patients are reviewed and reported. Consistently, high 2-year survival rates and overall response rates were demonstrated across the phase II trials in the range 42 -82 and 71 -100%, respectively. The toxicity profile seen with TPF-based regimens was acceptable. The primary toxicity was neutropenia, which together with gastrointestinal complaints accounted for the majority of adverse events. Given the encouraging phase II experience with TPF-based regimens, two large-scale phase III studies comparing TPF-based regimens with standard PF regimens are underway. The results have significant potential for validating the findings of the phase II studies, demonstrating improved survival and overall response of patients treated with docetaxel-based induction chemotherapy.

show abstract

Section: Docetaxel Plus Modified Pfl Regimensmentioning

confidence: 99%

Section: Docetaxel Plus Modified Pfl Regimensmentioning

confidence: 99%

Section: Docetaxel Plus Modified Pfl Regimensmentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Docetaxel has been shown to be more active than paclitaxel in 10 oesophageal cancer cell lines (Kawamura et al, 1997) and clinically active in patients with oesophageal adenocarcinoma (Einzig et al, 1996). Furthermore, its combination with cisplatin, fluorouracil and leucovorin showed an overall response (OR) of 94% and a complete response (CR) of 44% in patients with SCC of the head and neck, without altering the ability to administer definitive radiotherapy (Colevas et al, 1998).…”

mentioning

confidence: 99%

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer

Chiarion-Sileni

Corti

Ruol³

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

This study was performed to assess the efficacy and safety of docetaxel, cisplatin and fluorouracil combination in patients with unresectable locally advanced oesophageal squamous cell carcinoma. Treatment consisted of docetaxel 60 mg m À2 , cisplatin 75 mg m À2 on day 1 and fluorouracil 750 mg m À2 day À1 on days 2 -5, repeated every 3 weeks for three cycles, followed by carboplatin 100 mg m À2 week À1 for 5 weeks and concurrent radiotherapy (45 Gy in 25 fractions, 5 days week À1 ). After radiotherapy, eligible patients either underwent an oesophagectomy or received high dose rate endoluminal brachytherapy (HDR-EBT). Thirty-one out of 37 enrolled patients completed the planned chemotherapy and 30 completed chemoradiation. After completion of chemotherapy, 49% (95% CI: 32.2 -66.2) had a clinical response. Twelve patients (32%) underwent a resection, which was radical in 60% (postoperative mortality: 0%). A pathological complete response was documented in four patients (11% of enrolled, 30% of resected). The median survival was 10.8 months (95% CI: 8.1 -12.4), and the 1-and 2-year survival rates were 35.1 and 18.9%, respectively. Grade 3 -4 toxicities were neutropoenia 32%, anaemia 11%, non-neutropoenic infections 18%, diarrhoea 6% and oesophagitis 5%. Nine patients (24%) developed a tracheo-oesophageal fistula during treatment. Even if the addition of docetaxel to cisplatin and 5-fluorouracil (5-FU) seems to be more active than the cisplatin and 5-FU combination, an incremental improvement in survival is not seen, and the toxicity observed in this study population is of concern. In order to improve the prognosis of these patients, new drugs, combinations and strategies with a better therapeutic index need to be identified.

show abstract

“…Of these, 5-FU and cisplatin combination (FP) has been considered as an active and safe regimen for a long time (Colevas et al, 1998).…”

Section: Introductionmentioning

confidence: 99%

Low-Dose Docetaxel/Cisplatin - Leucovorin and 46 Hour Infusional Fluorouracil in Metastatic Gastric Carcinoma

Alıcı

Büyükberber²,

Alkış³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.

Cited by 93 publications

References 23 publications

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer

Low-Dose Docetaxel/Cisplatin - Leucovorin and 46 Hour Infusional Fluorouracil in Metastatic Gastric Carcinoma

Contact Info

Product

Resources

About